Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette–Guérin (BCG) in patients with superficial bladder cancer

Abstract

SUMMARYFew studies have analysed the antibody response during intravesical BCG immunotherapy for superficial bladder cancer. We have examined the evolution in serum antibody response against several heat shock proteins (hsp), including the recombinant mycobacterial hsp65 and the native protein P64 from BCG, GroEL from Escherichia coli (hsp60 family), recombinant mycobacterial hsp70 and the E. coli DnaK (hsp70 family), against purified protein derivative of tuberculin (PPD) and the AG85 complex of Mycobacterium bovis BCG, as well as against tetanus toxoid in 42 patients with a superficial bladder tumour, 28 treated with six intravesical BCG instillations and 14 patients used as controls. We also analysed the lymphoproliferative response of peripheral blood mononuclear cells against PPD in this population. Data of antibody responses at 6 weeks post BCG were available in all 28 patients,

Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy

“…In clinical practice, a burst of urinary Th1 cytokines IFNg, IL-12 and IL-2 has been observed after BCG therapy and is a common feature in BCG responders, whereas higher levels of the Th2 cytokines IL-10 and/or IL-6 appear to be associated with BCG failure de Reijke et al, 1996). Patients who failed BCG immunotherapy also showed higher antibody responses to BCG heat shock proteins in their sera (Zlotta et al, 1997). This nonpolarised activation of immune cells may represent a mechanism for BCG treatment failure in bladder cancer patients.…”

Prostaglandin E2 down-regulates viable Bacille Calmette–Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2in vitro

“…The activated effector cells kill target cells by both non-specific soluble factors and direct cell to cell contact. It is reported that patients who failed in BCG immunotherapy showed a higher antibody response to BCG heat-shock proteins in their sera [5] and higher levels of interleukin (IL)-6 and/or IL-10 in the urine of patients [6]. These studies indicate that Th2 immune responses are more easily induced than Th1 immune responses during BCG-immunotherapy and suppress cellular immune responses.…”

Molecular Chaperone GroEL – toward a Nano Toolkit in Protein Engineering, Production and Pharmacy

“…Immunogenic properties of mycobacterial chaperonins have been used in the development of therapeutic vaccines against cancer, autoimmune and other diseases, such as melanoma [51], diabetes [52], hepatitis B [53], and others, but there are not many examples of their practical use. One instance is that BCG vaccine, whose most potent immune-stimulating components are mycobacterial chaperones, is successfully used in intravesical treatment of superficial bladder cancer [54]. Also, there was a study that reached as far as the second stage of clinical trials, in which was used a fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and E7 protein of human papilloma virus type 16 (HPV16).…”